focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSUMM.L Share News (SUMM)

  • There is currently no data for SUMM

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Wednesday broker round-up UPDATE

Wed, 03rd Jul 2013 09:16

Aberdeen Asset Management: Bank of America reduces target price from 410p to 360p maintaining an underperform rating.ARM Holdings: UBS upgrades to buy from neutral, keeps target price at 970p.Cineworld: Investec ups target price from 347p to 360p and keeps a buy recommendation. N+1 Singer moves target price from 340p to 357p retaining a hold recommendation.Diageo: Espirito Santo cuts target price from 2280p to 2250p, while leaving its buy recommendation unchanged.Domino's Pizza Group: Canaccord Genuity reduces target price to 550p and downgrades to sell. Numis cuts view to add from buy. Oriel lowers to hold from add.Inchcape: Nomura takes target price from 485p to 500p staying with its neutral rating.Northgate: Goldman Sachs moves target price from 340p to 370p maintaining a neutral rating.Ocado: Jefferies raises target price from 80p to 275p, while keeping its hold recommendation.office2office: Panmure Gordon reduces target price from 120p to 67p and downgrades from buy to hold.Ophir Energy: HSBC Holdings increases target price from 530p to 558p reiterating an overweight rating.Persimmon: Deutsche Bank raises target price from 1060p to 1202p and stays with a hold recommendation. Goldman Sachs ups target price from 1756p to 1811p retaining a strong buy recommendation.PZ Cussons: Canaccord Genuity raises target price to 440p and upgrades from sell to buy.Randgold Resources: Citi increases target price from 3926p to 4491p and maintains a neutral rating.Reckitt Benckiser: Espirito Santo takes target price from 4140p to 4160p, but still recommends selling.SAB Miller: Espirito Santo reduces target price from 3520p to 3360p keeping a neutral rating.Serco Group: HSBC Holdings raises target price from 590p to 670p and upgrades to neutral.Smith (DS): Goldman Sachs lowers target price from 278p to 261p reiterating a neutral rating.Spirent Communications: Investec places both its target price (prev.: 150p) and its buy recommendation under review. Panmure Gordon moves target price from 176p to 166p, while its buy recommendation remains unchanged.Stagecoach: Morgan Stanley ups target price from 310p to 330p and retains an equal-weight rating.Summit Corporation: N+1 Singer shifts target price from 9p to 8.80p keeping a buy recommendation.Super Group: Investec increases target price from 843p to 878p leaving its buy recommendation unaltered.UNITE Group: JP Morgan moves target price from 425p to 450p and keeps an overweight rating.
More News
24 Feb 2016 12:35

Summit Therapeutics hails strong C-difficile findings

(ShareCast News) - Summit Therapeutics has reported that pre-clinical research into its treatment for the Clostridium difficile hospital superbug has found it to be a "novel and potent antibiotic". A peer-reviewed paper has been produced based on a study of Summit's ridinilazole versus current stand

Read more
19 Jan 2016 12:48

Summit Therapeutics gains worldwide patent protection for C-diff drug

(ShareCast News) - Summit Therapeutics has won a key patent protecting its novel antibiotic, ridinilazole, for the treatment of infections caused by the Clostridium difficile hospital superbug. The patent will grant Summit exclusivity in Europe for the use of ridinilazole in the treatment of CDI unt

Read more
19 Jan 2016 12:18

Summit Therapeutics Gets European Patent For Antibiotic Ridinilazole

Read more
22 Dec 2015 12:02

Port Erin Biopharma Continues To Look For Investments, Swings To Loss

Read more
17 Dec 2015 12:28

Summit Therapeutics Third Quarter Loss Widens As Pipeline Progresses

Read more
17 Nov 2015 12:17

Summit Therapeutics Extends Alliance With University Of Oxford

Read more
18 Sep 2015 12:50

Summit Therapeutics To Present Positive SMT19969 Data In San Diego

Read more
10 Sep 2015 11:11

Summit Therapeutics Finishes Enrolment For Phase II SMT19969 Trial

Read more
27 Aug 2015 11:48

Summit Therapeutics First Half Loss Widens As It Develops Pipeline

Read more
17 Aug 2015 12:33

Summit Therapeutics surges on positive clinical trial update

(ShareCast News) - Shares in Summit Therapeutics surged after the company said that its phase 1B clinical trial of SMT C1100 for the treatment of Duchenne muscular dystrophy met its primary objective and will now move on to a Phase 2 trial. The drug discovery and development company said half of the

Read more
14 Jul 2015 07:25

LONDON BRIEFING: Iran Nuclear Agreement Hits Oil Prices

Read more
13 Jul 2015 11:23

Summit Therapeutics Says Preclincal Data Support Its DMD Treatment

Read more
8 Jul 2015 12:04

Summit Therapeutics receives FDA fast-track decision for new antibiotic

Drug discovery and development company Summit Therapeutics has received approval from the US and Food Drug Administration (FDA) for its novel antibiotic. The FDA granted fast-track designation for the SMT19969 antibiotic which treats both duchenne muscular dystrophy and C. difficile infection (CDI).

Read more
8 Jul 2015 11:22

Summit Therapeutics Says CDI Antibiotic Given Fast Track Designation

Read more
7 Jul 2015 11:24

Summit Therapeutics Gets European Patent For Muscle Disease Treatment

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.